Articles

Podcasts

Videos

Clinical

Investigational therapy, ibrexafungerp, from Scynexis is being studied for fungal infections and is moving closer towards a goal of FDA approval later this year. 

Antifungal Shows Promising Results with Interim Phase 3 Data

Implications for antimicrobial use and antimicrobial resistance.

Bacterial Coinfections Among US Patients With Coronavirus Disease 2019

A £100 million donation from Ineos will fund collaborative effort across sciences.

New Oxford Institute Will Tackle Antibiotic Resistance

In a mature market of agents, the investigational therapy, ibrexafungerp, from Scynexis is looking at a few antifungal indications with a potential FDA approval in 2021. 

Developing a New Class of Antifungals

More than 13 million children did not receive their first DTP vaccine dose in 2019—and investigators anticipate the 2020 rate will be worse.

Fewer Infants in the Americas, Africa are Getting First-Year Vaccines

New data may evidence oral care as a therapeutic measure to reduce bacterial and viral spread.

Karen Giuliano, PhD: Oral Care to Reduce Hospital Infections

Multidrug-Resistant Infection is Diverse, Frequent in Hospital Setting

New data show ADA-recommended oral care for inpatients is associated with an 85% reduction in NVHAP infections at an 800-bed medical center over a year.

Oral Care May Prevent Hospital-Acquired Pneumonia Spread

Cefiderocol was noninferior to high-dose, extended-infusion meropenem in terms of all-case mortality in patients with gram-negative nosocomial pneumonia and showed similar clinical and microbiological efficacy to best available therapies in carbapenem-resistant, gram-negative bacterial infections, according to 2 recently released studies.

HEALTHCARE-ASSOCIATED INFECTIONS (HAI)